Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.75 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 7/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138070 | 0.87 | RHEB (0.69) | RHEBTRPA1ALDH1A1HTTPTGER3 | |
| SCHEMBL23709824 | 0.86 | RHEB (1.00) | RHEBALDH1A1HTTTUBB4ATUBB | |
| SCHEMBL1137495 | 0.85 | RHEB (0.62) | RHEBTRPA1ALDH1A1HTTBRD4 | |
| SCHEMBL7964114 | 0.83 | RHEB (0.77) | RHEBALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL23709599 | 0.82 | RHEB (0.61) | RHEBALDH1A1BRD4TUBB4ATUBB | |
| SCHEMBL23709588 | 0.80 | RHEB (0.67) | RHEBALDH1A1HTTTUBB4ATUBB | |
| SCHEMBL1138102 | 0.78 | RHEB (0.64) | RHEBALDH1A1BRD4PTGER3TUBB4A | |
| SCHEMBL1138637 | 0.75 | RHEB (0.56) | RHEB | |
| SCHEMBL1137699 | 0.74 | RHEB (0.59) | RHEBALDH1A1BRD4PTGER3 | |
| SCHEMBL1137747 | 0.74 | RHEB (0.59) | RHEBPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812388-B1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-02-23 | — | — | EP | disclosed |
| US-7714017-B2 | for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid | DECODE GENETICS, EHF (IS) | 2010-05-11 | — | — | US | disclosed |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-7598397-B2 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE GENETICS EHF (IS) | 2009-10-06 | — | — | US | disclosed |
| EP-1814881-A2 | CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1812388-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | DECODE CHEMISTRY, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2006044415-A2 | CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044000-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGS2 | RHEB 4081/4885TRPA1 826/4885ALDH1A1 903/4885 |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, PTGS2 | RHEB 4081/4885TRPA1 826/4885ALDH1A1 903/4885 |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGDR | RHEB 3142/4885TRPA1 1885/4885ALDH1A1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.